Fungal Pneumonia

Fungal pneumonia is rare disease in the general population but is a leading cause of death in immunocompromised patients.

Who are immunocompromised patients

  • Human immunodeficiency virus (HIV) infection
  • Acquired immunodeficiency syndrome (AIDS)
  • Malignancy (especially hematologic malignancies)
  • Transplant immunosuppression (including a bone marrow transplant)
  • Primary immunodeficiencies
  • Take steroids, had chemotherapy, or take other medications that suppress the immune
  • system
  • Critically ill

Fungal pneumonia caused by Aspergillus spp. and Cryptococcus spp. accounts for up to 25% of all lung transplantation patients,  17% of bone-marrow transplant patients and about 10-15% of HIV infected patients. Mortality due to aspergillosis and is up to 50 percent among these patients. Aspergillosis and cryptococcosis have mortality rates of 50-85% in transplant recipients and  other immunocompromised patients

 

Fungal pneumonia highlights

  • Severe opportunistic lung infection in people with weakened immune system*
  • Median mortality rate  — from 5% to 40% in those who receive treatment***
  • Mortality rate 100% without therapy***
  • Characterized by  acute inflammation  and respiratory distress
There are NO safe, effective inhalable antifungal drugs for  the treatment of fungal pneumonia

TGV-Therapeutics’ clinical drug candidate against Fungal Pneumonia —  Mul-1867

Mul-1867 provide  treatment and protection that is:

  • More effective — no fungi are resistant to Mul-1867
  • Penetrate fungal biofilms
  • Active against azole-resistant and amphotericin B resistant fungi
  • Active against mixed bacterial-fungal infections
  • Inactivate fungal spores